Centralized databases, reduced competition for patients, and higher starting doses are among some of the benefits to conducting research in Poland, which ranks seventh in Europe for clinical trial participation, says Moleculin CEO.
Eight site networks team up to form hyperCore International – “the network of networks” – with locations from Lima, Peru to Calgary, Canada, says CEO, who stresses the company's partnership model as key to its success.
GSK announces that it will spend $100m to expand production capacity for components of Shingrix, amid a US market where demand outstrips supply of its shingles vaccine.
Casey Orvin, named the new president of SCRS earlier this year, aims to ensure that sites “stay in the forefront of the minds of sponsors and CROs” – and have a seat at the table as equal partners in the industry.
The International Vaccine Institute plans to conduct a Phase III clinical trial for a typhoid conjugate vaccine as part of which it will put in place infrastructure and a robust training program, including good clinical practice training.
Using RWD and RWE to make data actionable and patient centric can be a gamechanger in the health care industry’s research capabilities, according to LMC Manna research executive.
Medable has received $3.5m to further develop its end-to-end platform for digitally-enabled clinical trials, which can be used at an individual, study, or population level.
LabCorp’s Covance Drug Development segment is set to acquire Envigo’s nonclinical research services business for $485m – while Envigo will purchase Covance’s research products business.
On the path to first-in-human clinical trials one of the main challenges is “velocity, ensuring rapid delivery of delivered drug product into the clinical program,” says CDMO.
Oncology and immunotherapies are the top two indications for global clinical research – and are driving a significant growth in the market demand for HPAPIs, says Patheon executive.
Senator Flake will discuss regulatory guidance impacting innovation and his perspective on the state of the industry during his keynote address at CPhI North America.
Jordan-based MS Pharma announces the acquisition of the Greek generic manufacturer Genepharm, aiming to add cardiovascular, CNS and oncology products to its portfolio.
Novotech signs on two major hospitals to its CRO partnership program in South Korea – a market seeing greater interest from North American and European companies.
I-Mab and WuXi Biologics extend their strategic partnership for biologics process development as well as clinical and commercial manufacturing to accelerate drug development in China and abroad.
Circuit Clinical is providing digital and clinical services as part of its collaboration with a NY-based cancer center, patients at which will have expanded opportunities to participate in clinical trials.
Completion of early-stage development site expansion at the Illinois Science and Technology Park supplies Chicago-based drug companies with refrigeration services for complex APIs.
Acorn AI is designed to answer questions across all phases of drug development, making data “liquid” to help pharma make quick “go/no-go” decisions, accelerate clinical trials, and demonstrate value.
Patients in Southern and Eastern Europe wait on average five times as long for the same treatments as patients in Northern and Western Europe, an EFPIA report finds.
China-based pharmaceutical companies betting big and small biopharma able to quickly innovate will drive the use of AI for drug discovery – a market some analysts predict will reach a valuation of $20bn by 2024.
Virtual trials are poised to scale, says the CEO of Transparency Life Sciences, which recently conducted a siteless study to assess the feasibility and ease of collecting research-grade clinical data from subjects remotely.
The online marketplace for outsourced research launches its first original service, which will provide researchers with on-demand insights into clinical trials – including trends in what is ‘hot’ and what is ‘not,’ says CBO.
Sharp’s clinical services center is approved by the MHRA and now ready to offer services for serialization and trial management while reducing carbon footprint with the addition of solar panel systems.
Natural history studies provide researchers with a better understanding of a disease’s progression, supporting clinical trial design, among other benefits, say industry experts commenting on the FDA’s new draft guidance.
Taconic Biosciences’ new solution enables researchers to generate and maintain mice with custom microbiome profiles, alterations to which can significantly affect drug efficacy.
Enesi Pharma and OVG sign a collaborative agreement, hoping to combine a promising ingredient and an innovative delivery method to produce a plague vaccine.
The $74bn deal appeared to be fraying around edges, as certain shareholders voiced dissent, but a vote saw the deal pass with support from more than 75% of investors.
Charles River Laboratories has extended its ongoing collaboration with the CHDI Foundation by five-years – and is closing its San Diego, CA-based research model production facility.
monARC Bionetworks' new app enables patients to track symptoms between clinic visits – while also passively collecting environmental data, such as location and air quality.
Using automated chain-of-custody systems can save study sponsors and CROs a minimum of $1.3m per clinical trial in operating costs, according to a recent report from Almac.
NC-based FHI Clinical last week officially launched as a new full-service contract research organization with a global team the “right size” to adjust when needed, says CEO.
Catalent Pharma Solutions has opened its new, 30,000-square-foot Shanghai, China-based clinical supply facility, which is expected to employ up to 100.
An observation by the US FDA notes that Aurobindo had no established control procedures to monitor its manufacturing process, resulting in batches contaminated with unidentified material.
